180 related articles for article (PubMed ID: 28616432)
21. Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina.
Hwang J; Lee HC; Kim BW; Yang MJ; Park JS; Park JH; Lee HW; Oh J; Choi JH; Cha KS; Hong TJ; Song S; Kim SP
J Cardiol; 2013 Aug; 62(2):77-81. PubMed ID: 23731922
[TBL] [Abstract][Full Text] [Related]
22. Relation of Neutrophil to Lymphocyte Ratio With Periprocedural Myocardial Damage in Patients Undergoing Elective Percutaneous Coronary Intervention.
Bressi E; Mangiacapra F; Ricottini E; Cavallari I; Colaiori I; Di Gioia G; Creta A; Di Sciascio G
Am J Cardiol; 2016 Oct; 118(7):980-4. PubMed ID: 27515894
[TBL] [Abstract][Full Text] [Related]
23. Troponin I elevation and cardiac events after percutaneous coronary intervention.
Ricciardi MJ; Davidson CJ; Gubernikoff G; Beohar N; Eckman LJ; Parker MA; Bonow RO
Am Heart J; 2003 Mar; 145(3):522-8. PubMed ID: 12660677
[TBL] [Abstract][Full Text] [Related]
24. [Effects of pretreatment with recombinant human B-type natriuretic peptide on infarct size in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention].
Li S; Fu X; Dai Y; Liu C; Wang Y; Li W; Wu W; Gu X; Hao G; Fan W; Miao Q; Jiang Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2015 Nov; 43(11):954-9. PubMed ID: 26888806
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Accuracy of Post Procedural Creatine Kinase, MB Form can Predict Long-Term Outcomes in Patients Undergoing Selective Percutaneous Coronary Intervention?
Maadani M; Parchami-Ghazaee S; Barati G; Soltani M; Amiri E; Ghadrdoost B; Heidarali M
Res Cardiovasc Med; 2014 Feb; 3(1):e11738. PubMed ID: 25478525
[TBL] [Abstract][Full Text] [Related]
26. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.
Chen WH; Lee PY; Ng W; Tse HF; Lau CP
J Am Coll Cardiol; 2004 Mar; 43(6):1122-6. PubMed ID: 15028378
[TBL] [Abstract][Full Text] [Related]
27. Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.
Kazmi DH; Kapoor A; Sinha A; Ambesh P; Kashyap S; Khanna R; Kumar S; Garg N; Tewari S; Goel PK
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S365-S371. PubMed ID: 30595291
[TBL] [Abstract][Full Text] [Related]
28. Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty.
Abbas SA; Glazier JJ; Wu AH; Dupont C; Green SF; Pearsall LA; Waters DD; McKay RG
Clin Cardiol; 1996 Oct; 19(10):782-6. PubMed ID: 8896910
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Sardella G; Conti G; Donahue M; Mancone M; Canali E; De Carlo C; Di Roma A; Calcagno S; Lucisano L; Fedele F
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E36-43. PubMed ID: 22517610
[TBL] [Abstract][Full Text] [Related]
30. Periprocedural use of tirofiban in elective percutaneous coronary intervention for long coronary lesions in stable patients with overlapping drug-eluting stents--the PETITION study: a prospective, randomized, multicenter study.
Zhang Q; Wang XL; Liao ML; Hu J; Yang ZK; Ding FH; Zhang JS; Du R; Zhu TQ; Shen WF; Zhang RY
Catheter Cardiovasc Interv; 2015 Mar; 85 Suppl 1():762-9. PubMed ID: 25630513
[TBL] [Abstract][Full Text] [Related]
31. Effects of tirofiban plus clopidogrel versus clopidogrel plus provisional abciximab on biomarkers of myocardial necrosis in patients with non-ST-elevation acute coronary syndromes treated with early aggressive approach. Results of the CLOpidogrel, upstream TIrofiban, in cath Lab Downstream Abciximab (CLOTILDA) study.
Leoncini M; Toso A; Maioli M; Bellandi F; Badia T; Politi A; De Servi S; Dabizzi RP
Am Heart J; 2005 Sep; 150(3):401. PubMed ID: 16169315
[TBL] [Abstract][Full Text] [Related]
32. Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention.
Li J; Xu JP; Zhao XZ; Sun XJ; Xu ZW; Song SJ
Cardiology; 2014; 127(2):133-9. PubMed ID: 24335026
[TBL] [Abstract][Full Text] [Related]
33. [Evaluation of dynamic cardiac troponin I concentrations and C-reactive protein in the monitoring of myocardial infarction in patients with repeated myocardial infarction].
Plak M; Orliński L; Łobos M; Ciesielczyk M; Wlazeł RN; Paradowski MT
Pol Merkur Lekarski; 2010 Jun; 28(168):444-9. PubMed ID: 20642101
[TBL] [Abstract][Full Text] [Related]
34. Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study.
Cavallini C; Savonitto S; Violini R; Arraiz G; Plebani M; Olivari Z; Rubartelli P; Battaglia S; Niccoli L; Steffenino G; Ardissino D;
Eur Heart J; 2005 Aug; 26(15):1494-8. PubMed ID: 15741227
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.
Jeremias A; Albirini A; Ziada KM; Chew DP; Brener SJ; Topol EJ; Ellis SG
Am Heart J; 2002 Jun; 143(6):1040-5. PubMed ID: 12075261
[TBL] [Abstract][Full Text] [Related]
36. Glycogen phosphorylase isoenzyme BB, creatine kinase isoenzyme MB and troponin I for monitoring patients with percutaneous coronary intervention - a pilot study.
Skitek M; Kranjec I; Jerin A
Med Glas (Zenica); 2014 Feb; 11(1):13-8. PubMed ID: 24496335
[TBL] [Abstract][Full Text] [Related]
37. The impact of micro troponin leak on long-term outcomes following elective percutaneous coronary intervention.
Milani RV; Fitzgerald R; Milani JN; Lavie CJ
Catheter Cardiovasc Interv; 2009 Nov; 74(6):819-22. PubMed ID: 19670308
[TBL] [Abstract][Full Text] [Related]
38. High high-density lipoprotein-cholesterol reduces risk and extent of percutaneous coronary intervention-related myocardial infarction and improves long-term outcome in patients undergoing elective percutaneous coronary intervention.
Sattler KJ; Herrmann J; Yün S; Lehmann N; Wang Z; Heusch G; Sack S; Erbel R; Levkau B
Eur Heart J; 2009 Aug; 30(15):1894-902. PubMed ID: 19474052
[TBL] [Abstract][Full Text] [Related]
39. A randomized study assessing the effects of pretreatment with cilostazol on periprocedural myonecrosis after percutaneous coronary intervention.
Kim BK; Oh SJ; Yoon SJ; Jeon DW; Ko YG; Yang JY
Yonsei Med J; 2011 Sep; 52(5):717-26. PubMed ID: 21786434
[TBL] [Abstract][Full Text] [Related]
40. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study.
Zemánek D; Branny M; Martinkovičová L; Hájek P; Malý M; Tesař D; Tomašov P; Veselka J
Int J Cardiol; 2013 Oct; 168(3):2494-7. PubMed ID: 23597577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
